DexCom (DXCM) Stock Forecast & Price Target

DexCom is supported by stronger-than-expected 3Q results, with Adjusted EPS of $0.72 on revenue of $1.345 billion and Adjusted EBITDA of $435 million, plus raised guidance that implies 12-13% revenue growth for 2026 and margin expansion. Its outlook is further strengthened by 65.1% non-GAAP gross margin in 3Q, the G7 15-Day rollout, lower-cost manufacturing in Malaysia, Arizona, and Ireland, and a $1 billion share repurchase authorization that signals confidence in free-cash-flow generation. The long-term thesis is reinforced by expanding reimbursement opportunities in the large non-insulin Type 2 market, including CONNECT data showing a 6-month A1c reduction of -1.6% versus -0.7% in control and ~97% adherence, which should support broader adoption and durable utilization.

DexCom is exposed to several fundamental headwinds, including unfavorable healthcare regulation, pricing and reimbursement pressure, technology risk, competition, and geopolitical risk, all of which can constrain growth and margins. Its CGM systems also face meaningful product limitations, with compression lows being the most notable sensor-related issue, since sleeping or lying on the sensor arm can produce falsely low readings and reduce the usefulness of overnight glucose analysis. Although this problem is common across multiple brands and DexCom suggests adjusting sensor placement, such limitations can weaken user confidence, slow adoption, and leave the company vulnerable as rivals improve performance.